HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression

Carcinogenesis

Volumn 34, Issue 8, 2013, Pages 1699-1707

  Philip, Beatrice ^a   Ito, Koichi ^a   Moreno Sánchez, Rafael ^b   Ralph, Stephen J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1;

BIOACCUMULATION; CANCER STEM CELL; CARCINOGENESIS; CELL PROTECTION; CELL RENEWAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; IMMUNOREGULATION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGEN TENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84881539307     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt209     Document Type: Review

References (146)

1. Jögi, A. et al. (2002) Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl Acad. Sci. USA, 99, 7021-7026.
2. Zou, L., et al. (2008) Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J., 22, 355-364.
3. Awale, S., et al. (2006) Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res., 66, 1751-1757.
4. Land, S.C., et al. (2007) Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem., 282, 20534-20543.
5. Mu, D., et al. (2005) Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp. Neurol., 195, 407-415.
6. Semenza, G.L., et al. (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem., 269, 23757-23763.
7. Marín-Hernández, A., et al. (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev. Med. Chem., 9, 1084-1101.
8. Rohwer, N., et al. (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat., 14, 191-201.
9. Lara, P.C., et al. (2009) Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat. Oncol., 4, 29.
10. Bracken, C.P., et al. (2006) Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. J. Biol. Chem., 281, 22575-22585.
11. Unruh, A., et al. (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene, 22, 3213-3220.
12. Schilling, D., et al. (2012) Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1a. PLoS One, 7, e31110.
13. Schilling, D., et al.. (2012) Basal HIF-1a expression levels are not predictive for radiosensitivity of human cancer cell lines. Strahlenther. Onkol., 188, 353-358.
14. Dewhirst, M.W., et al. (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer, 8, 425-437.
15. Zhong, H., et al. (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res., 59, 5830-5835.
16. Hung, J.J., et al. (2009) Prognostic significance of hypoxia-inducible factor- 1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax, 64, 1082-1089.
17. Berra, E., et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J., 22, 4082-4090.
18. Zhou, Y.D., et al. (1997) Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc. Natl Acad. Sci. USA, 94, 713-718.
19. Déry, M.A., et al. (2005) Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol., 37, 535-540.
20. Loboda, A., et al. (2010) HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells, 29, 435-442.
21. Gordan, J.D., et al. (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell, 11, 335-347.
22. Takahashi-Makise, N., et al.. (2009) On the mechanism of iron sensing by IRP2: new players, new paradigms. Nat. Chem. Biol., 5, 874-875.
23. Dayan, F., et al. (2006) The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res., 66, 3688-3698.
24. Yang, M.H., et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol., 10, 295-305.
25. Astuti, D., et al. (2011) Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr. Relat. Cancer, 18, 73-83.
26. Taylor, M.S. (2001) Characterization and comparative analysis of the EGLN gene family. Gene, 275, 125-132.
27. Acker, T., et al. (2004) Cellular oxygen sensing need in CNS function: physiological and pathological implications. J. Exp. Biol., 207(Pt 18), 3171-3188.
28. Li, X.Y., et al. (2008) Expression, purification and characterization of human PHD1 in Escherichia coli. J. Biochem., 144, 555-561.
29. Appelhoff, R.J., et al. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem., 279, 38458-38465.
30. Schofield, C.J., et al. (2004) Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol., 5, 343-354.
31. Henze, A.T., et al. (2010) Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res., 70, 357-366.
32. Epstein, A.C., et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107, 43-54.
33. Metzen, E., et al. (2005) Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem. J., 387(Pt 3), 711-717.
34. Takeda, K., et al. (2006) Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol., 26, 8336-8346.
35. Tan, E.Y., et al. (2007) Cytoplasmic location of factor-inhibiting hypoxiainducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Res., 9, R89.
36. Bárdos, J.I., et al. (2005) Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta., 1755, 107-120.
37. Lando, D., et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev., 16, 1466-1471.
38. Zhang, N., et al. (2010) The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab., 11, 364-378.
39. Melmon, K.L., et al. (1964) Lindau's disease. Review of the literature and study of a large kindred. Am. J. Med., 36, 595-617.
40. Cai, Q., et al. (2010) Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One, 5, e9720.
41. Shiao, Y.H., et al. (2000) The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res., 60, 2816-2819.
42. Frew, I.J., et al. (2008) pVHL: a multipurpose adaptor protein. Sci. Signal., 1, pe30.
43. Clifford, S.C., et al. (2001) The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene, 20, 5067-5074.
44. Kaelin, W.G. (2005) Proline hydroxylation and gene expression. Annu. Rev. Biochem., 74, 115-128.
45. Kaelin G. Jr (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer, 2, 673-682.
46. Wu, S., et al. (2008) Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol. Ther., 16, 1227-1234.
47. Iliopoulos, O., et al. (1995) Tumour suppression by the human von Hippel- Lindau gene product. Nat. Med., 1, 822-826.
48. Cheng, J., et al. (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 131, 584-595.
49. MacKenzie, E.D., et al. (2007) Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol., 27, 3282-3289.
50. Yao, L., et al. (2010) Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab., 95, 1469-1472.
51. Kim, W.Y., et al. (2004) Role of VHL gene mutation in human cancer. J. Clin. Oncol., 22, 4991-5004.
52. Schlisio, S. (2009) Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. J. Cell. Mol. Med., 13, 4104-4112.
53. Lu, H., et al. (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem., 277, 23111-23115.
54. López-Jiménez, E., et al. (2010) Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol. Endocrinol., 24, 2382-2391.
55. Brière, J.J., et al. (2005) Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet., 14, 3263-3269.
56. Selak, M.A., et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85.
57. Pollard, P.J., et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet., 14, 2231-2239.
58. Thirstrup, K., et al. (2011) Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. Pharmacol. Res., 64, 268-273.
59. Gumaa, K.A., et al. (1969) The pentose phosphate pathway of glucose metabolism. Enzyme profiles and transient and steady-state content of intermediates of alternative pathways of glucose metabolism in Krebs ascites cells. Biochem. J., 115, 1009-1029.
60. Marín-Hernández, A., et al. (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an overexpressed but strongly product-inhibited hexokinase. FEBS J., 273, 1975-1988.
61. Koivunen, P., et al. (2007) Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem., 282, 4524-4532.
62. Lu, H., et al. (2005) Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem., 280, 41928-41939.
63. Tuderman, L., et al. (1977) Mechanism of the prolyl hydroxylase reaction. 1. Role of co-substrates. Eur. J. Biochem., 80, 341-348.
64. Maher, E.R. (2006) Genetics of phaeochromocytoma. Br. Med. Bull., 79-80, 141-151.
65. Hirsilä,M., et al. (2003) Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem., 278, 30772-30780.
66. Myllylä,R., et al. (1977) Mechanism of the prolyl hydroxylase reaction. 2. Kinetic analysis of the reaction sequence. Eur. J. Biochem., 80, 349-357.
67. O'Flaherty, L., et al. (2010) Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. Hum. Mol. Genet., 19, 3844-3851.
68. Barker, K.T., et al. (2002) Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br. J. Cancer, 87, 446-448.
69. Kiuru, M., et al. (2002) Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res., 62, 4554-4557.
70. Yogev, O., et al. (2010) Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response. PLoS Biol., 8, e1000328.
71. Zhao, S., et al. (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science, 324, 261-265.
72. Hao, H.X., et al. (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 325, 1139-1142.
73. Linehan, W.M., et al. (2010) The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol., 7, 277-285.
74. Smith, T.G., et al. (2006) Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med., 3, e290.
75. Biswas, S., et al. (2010) Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J. Oncol., 2010, 757908.
76. Wiesner, R.J., et al. (1988) Pathways of succinate formation and their contribution to improvement of cardiac function in the hypoxic rat heart. Biochem. Med. Metab. Biol., 40, 19-34.
77. Ralph, S.J., et al. (2010) The causes of cancer revisited: et al."mitochondrial malignancy" and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol. Aspects Med., 31, 145-170.
78. Semenza, G.L. (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci., 33, 207-214.
79. Ito, K., et al. (2011) Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis, 14, 293-307.
80. Hosford, G.E., et al. (2003) Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung. Am. J. Physiol. Lung Cell. Mol. Physiol., 285, L161-L168.
81. Skuli, N., et al. (2009) Endothelial deletion of hypoxia-inducible factor- 2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood, 114, 469-477.
82. Koh, M.Y., et al. (2011) The hypoxia-associated factor switches cells from HIF-1a- to HIF-2a-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res., 71, 4015-4027.
83. Rodríguez-Enríquez, S., et al. (2010) Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma. Int. J. Biochem. Cell Biol., 42, 1744-1751.
84. Chu, Y.W., et al. (1997) Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol., 17, 353-360.
85. Louie, E., et al. (2010) Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res., 12, R94.
86. Cho, K.B., et al. (2010) Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett., 293, 230-239.
87. Wolfer, A., et al. (2011) MYC and metastasis. Cancer Res., 71, 2034-2037.
88. Jones, R.G., et al. (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev., 23, 537-548.
89. López-Lázaro, M. (2006) HIF-1: hypoxia-inducible factor or dysoxiainducible factor?. FASEB J., 20, 828-832.
90. Semenza, G., et al.. (2012) The role of hypoxia-inducible factors in oxygen sensing by the carotid body. In Nurse, C.A., et al.. (eds) Arterial Chemoreception. Springer, The Netherlands, pp. 1-5.
91. Sermeus, A., et al. (2011) Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis., 2, e164.
92. Vafa, O., et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogeneinduced genetic instability. Mol. Cell, 9, 1031-1044.
93. Castells, M., et al. (2012) Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int. J. Mol. Sci., 13, 9545-9571.
94. Hujanen, E.S., et al. (1985) Migration of tumor cells to organ-derived chemoattractants. Cancer Res., 45, 3517-3521.
95. Jiang, J., et al. (2011) EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol. Ther., 11, 714-723.
96. Zhang, Q., et al. (2011) Wnt/β-catenin signaling enhances hypoxiainduced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1a signaling. Carcinogenesis, 34, 962-973.
97. Lundgren, K., et al. (2009) Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br. J. Cancer, 101, 1769-1781.
98. Imai, T., et al. (2003) Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol., 163, 1437-1447.
99. Cannito, S., et al. (2008) Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis, 29, 2267-2278.
100. Yoo, Y.G., et al. (2011) HIF-1a mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression. Sci. Signal., 4, pt4.
101. Sahlgren, C., et al. (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Natl Acad. Sci. USA, 105, 6392-6397.
102. Swann, J.B., et al. (2007) Immune surveillance of tumors. J. Clin. Invest., 117, 1137-1146.
103. Doedens, A.L., et al. (2010) Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res., 70, 7465-7475.
104. Yang, M., et al. (2009) Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology, 128(1 suppl.), e237-e249.
105. Facciabene, A., et al. (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475, 226-230.
106. Eltzschig, H.K., et al. (2004) Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood, 104, 3986-3992.
107. Ohta, A., et al. (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA, 103, 13132-13137.
108. Lewis, C., et al. (2005) Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol., 167, 627-635.
109. Lee, C.T., et al. (2010) Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int. J. Hyperthermia, 26, 232-246.
110. Lukashev, D., et al. (2006) Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J. Immunol., 177, 4962-4965.
111. Le, Q.T., et al. (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol., 23, 8932-8941.
112. Ito, K., et al. (2012) Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer and Metastasis Rev., 31, 763-778.
113. Shim, H., et al. (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl Acad. Sci. USA, 94, 6658-6663.
114. Elson, D.A., et al. (2000) Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res., 60, 6189-6195.
115. Singer, K., et al. (2011) Suppression of T-cell responses by tumor metabolites. Cancer Immunol. Immunother., 60, 425-431.
116. Castello, P.R., et al. (2006) Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. Cell Metab., 3, 277-287.
117. Frezza, C., et al. (2011) Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One, 6, e24411.
118. Fischer, K., et al. (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 109, 3812-3819.
119. Fyles, A., et al. (2002) Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol., 20, 680-687.
120. Keith, B., et al. (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell, 129, 465-472.
121. Heddleston, J.M., et al. (2010) Hypoxia inducible factors in cancer stem cells. Br. J. Cancer, 102, 789-795.
122. Liang, D., et al. (2012) The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer, 12, 201.
123. Mathieu, J., et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res., 71, 4640-4652.
124. Chen, J., et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 488, 522-526.
125. Al-Ejeh, F., et al. (2011) Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis, 32, 650-658.
126. Kim, Y., et al. (2009) Hypoxic tumor microenvironment and cancer cell differentiation. Curr. Mol. Med., 9, 425-434.
127. Bhaskara, V.K., et al. (2012) Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. PLoS One, 7, e30905.
128. Rizzino, A. (2009) Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip. Rev. Syst. Biol. Med., 1, 228-236.
129. Peng, S., et al. (2010) Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene, 29, 2153-2159.
130. Ben-Porath, I., et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507.
131. Koh, M.Y., et al. (2012) Passing the baton: the HIF switch. Trends Biochem. Sci., 37, 364-372.
132. Iida, H., et al. (2012) Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int. J. Oncol., 40, 71-79.
133. Franovic, A., et al. (2009) Human cancers converge at the HIF-2alpha oncogenic axis. Proc. Natl Acad. Sci. USA, 106, 21306-21311.
134. Chaudary, N., et al. (2007) Hypoxia and metastasis. Clin. Cancer Res., 13, 1947-1949.
135. Hofmann, M., et al. (2006) Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia, 8, 89-95.
136. Shannon, A.M., et al. (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev., 29, 297-307.
137. Bristow, R.G., et al. (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer, 8, 180-192.
138. López-Lázaro, M. (2006) Hypoxia-inducible factor 1 as a possible target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev., 15, 2332-2335.
139. Garber, K. (2005) New drugs target hypoxia response in tumors. J. Natl Cancer Inst., 97, 1112-1114.
140. Bennewith, K.L., et al. (2011) Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer, 11, 504.
141. Patterson, A.V., et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res., 13, 3922-3932.
142. FDA approves Proacta IND application for PR610. Pharmaceutical Business Review. http://regulatoryaffairs.pharmaceutical-business-review. com/news/fda-approves-proacta-ind-application-for-pr610-300812 (30 August 2012).
143. Wilson, W.R., et al. (2011) Targeting hypoxia in cancer therapy. Nat. Rev. Cancer, 11, 393-410.
144. Yu, B., et al. (2012) Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella typhimurium strain. Sci. Rep., 2, 436.
145. St Jean, A.T., et al. (2008) Bacterial therapies: completing the cancer treatment toolbox. Curr. Opin. Biotechnol., 19, 511-517.
146. Hanahan, D., et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.